Hepatitis Research Today is a free monthly online journal that collates and summarizes the latest research about Hepatitis, including details on hepatitis a, b, c, causes, symptoms.

Volume 1 (2006), Issue 6 (June)

1. HLA typing associated with hepatitis B E antigen seroconversion in children with chronic hepatitis B virus infection: a long-term prospective sibling cohort study in Taiwan.
   J Pediatr, 148(5): 647-651. [Abstract] [Full-text]
2. Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers.
   Vaccine, 24(21): 4482-9. [Abstract] [Full-text]
3. Possible association of vigorous hepatitis B virus replication with the development of fulminant hepatitis.
   J Gastroenterol, 41(4): 383-7. [Abstract] [Full-text]
4. Etiological investigation of fatal liver failure during the course of chronic hepatitis B in southeast China.
   J Gastroenterol, 41(4): 347-51. [Abstract] [Full-text]
5. Cost-effectiveness of chronic hepatitis C treatment with thymosin alpha-1.
   Arch Med Res, 37(5): 663-73. [Abstract] [Full-text]
6. Integrated metabonomic analysis of bromobenzene-induced hepatotoxicity: novel induction of 5-oxoprolinosis.
   J Proteome Res, 5(6): 1448-59. [Abstract] [Full-text]
7. Effectiveness of a hepatitis A vaccination program for migrant children in Amsterdam, The Netherlands (1992-2004).
   Vaccine, 24(23): 4962-8. [Abstract] [Full-text]
8. Isolation of neutrophils from mouse liver: A novel method to study effector leukocytes during inflammation.
   J Immunol Methods, 312(1): 68-78. [Abstract] [Full-text]
9. Discriminant function based on hyaluronic acid and its degrading enzymes and degradation products for differentiating cirrhotic from non-cirrhotic liver diseased patients in chronic HCV infection.
   Clin Chim Acta, 369(1): 66-72. [Abstract] [Full-text]
10. Immune suppression as the etiology of failure to detect anti-HBc antibodies in patients with chronic hepatitis B virus infection.
    J Clin Microbiol, 44(6): 2250-3. [Abstract] [Full-text]
11. Phylogenetic analysis of previously nontypeable hepatitis C virus isolates from Argentina.
    J Clin Microbiol, 44(6): 2229-32. [Abstract] [Full-text]
12. Unusual naturally occurring humoral and cellular mutated epitopes of hepatitis B virus in a chronically infected argentine patient with anti-HBs antibodies.
    J Clin Microbiol, 44(6): 2191-8. [Abstract] [Full-text]
13. Analysis of the 5' noncoding region versus the NS5b region in genotyping hepatitis C virus isolates from blood donors in France.
    J Clin Microbiol, 44(6): 2051-6. [Abstract] [Full-text]
14. Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2).
    J Clin Microbiol, 44(6): 1994-7. [Abstract] [Full-text]
15. Development of humanized mice for the study of hepatitis C virus infection.
    Transplant Proc, 38(4): 1181-4. [Abstract] [Full-text]
16. Antiviral therapy for hepatitis C virus recurrence following liver transplantation: long-term results from a single center experience.
    Transplant Proc, 38(4): 1127-30. [Abstract] [Full-text]
17. Intractable pruritus in patients with hepatitis C virus.
    Transplant Proc, 38(4): 1089-91. [Abstract] [Full-text]
18. Kidney transplantation from donors with viral B and C hepatitis.
    Transplant Proc, 38(4): 996-8. [Abstract] [Full-text]
19. Hepatitis B virus blood screening: unfinished agendas.
    Vox Sang, 91(1): 1-12. [Abstract] [Full-text]
20. Steroid therapy for a case of severe drug-induced cholestasis.
    Ann Pharmacother, 40(6): 1196-9. [Abstract] [Full-text]
21. Amelioration of fumonisin B1 hepatotoxicity in mice by depletion of T cells with anti-Thy-1.2.
    Toxicology, 223(3): 191-201. [Abstract] [Full-text]
22. Novel subtypes (subgenotypes) of hepatitis B virus genotypes B and C among chronic liver disease patients in the Philippines.
    J Gen Virol, 87: 1873-82. [Abstract] [Full-text]
23. Immunization coverage and risk factors for failure to immunize within the Expanded Programme on Immunization in Kenya after introduction of new Haemophilus influenzae type b and hepatitis b virus antigens.
    BMC Public Health, 6: 132. [Abstract] [Full-text]
24. Adherence to the screening program for HBV infection in pregnant women delivering in Greece.
    BMC Infect Dis, 6: 84. [Abstract] [Full-text]
25. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy.
    Hepatology, 43(5): 954-60. [Abstract] [Full-text]
26. Liver disease in Egypt: hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors.
    Hepatology, 43(5): 915-22. [Abstract] [Full-text]
27. Duration of peginterferon therapy in acute hepatitis C: a randomized trial.
    Hepatology, 43(5): 923-31. [Abstract] [Full-text]
28. A 12-week clevudine therapy showed potent and durable antiviral activity in hbeag-positive chronic hepatitis B.
    Hepatology, 43(5): 982-8. [Abstract] [Full-text]
29. Serum proteome to predict virologic response in patients with hepatitis C treated by pegylated interferon plus ribavirin.
    Gastroenterology, 130(7): 2189-97. [Abstract] [Full-text]
30. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B.
    Gastroenterology, 130(7): 2039-49. [Abstract] [Full-text]
31. Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature.
    Liver Int, 26(5): 625-9. [Abstract] [Full-text]
32. Distinguishing nonalcoholic steatohepatitis from fatty liver: serum-free fatty acids, insulin resistance, and serum lipoproteins.
    Liver Int, 26(5): 566-71. [Abstract] [Full-text]
33. Differential findings for CD14-positive hepatic monocytes/macrophages in primary biliary cirrhosis, chronic hepatitis C and nonalcoholic steatohepatitis.
    Liver Int, 26(5): 559-65. [Abstract] [Full-text]
34. Clinical and HLA phenotypes of type 1 autoimmune hepatitis in North American patients outside DR3 and DR4.
    Liver Int, 26(5): 552-8. [Abstract] [Full-text]
35. Surveillance of hepatocellular carcinoma in patients with hepatitis C virus infection may improve patient survival.
    Liver Int, 26(5): 543-51. [Abstract] [Full-text]
36. Impact of pegylated interferon alpha-2B and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series.
    Liver Int, 26(5): 529-35. [Abstract] [Full-text]
37. Twenty-four weeks of interferon alpha-2b in combination with ribavirin for Japanese hepatitis C patients: sufficient treatment period for patients with genotype 2 but not for patients with genotype 1.
    Liver Int, 26(5): 520-8. [Abstract] [Full-text]
38. Interleukin-10 or tumor necrosis factor-alpha polymorphisms and the natural course of hepatitis C virus infection in a hyperendemic area of Japan.
    Cytokine, 34(1): 24-31. [Abstract] [Full-text]
39. Pharmacoeconomics applied to chronic hepatitis C.
    Braz J Infect Dis, 10(1): 51-4. [Abstract] [Full-text]
40. Clinical and epidemiological features of patients with chronic hepatitis C co-infected with HIV.
    Braz J Infect Dis, 10(1): 17-21. [Abstract] [Full-text]
41. Peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy.
    Braz J Infect Dis, 10(1): 11-6. [Abstract] [Full-text]
42. The development of connective tissue diseases in patients with autoimmune hepatitis: a case series.
    Semin Arthritis Rheum, 35(6): 344-8. [Abstract] [Full-text]
43. Chronic hepatitis B: current testing strategies.
    Clin Gastroenterol Hepatol, 4(6): 666-76. [Abstract] [Full-text]
44. Infected health care workers and patient safety: a double standard.
    Am J Infect Control, 34(5): 313-9. [Abstract] [Full-text]
45. Effect of pentoxifylline on levels of pro-inflammatory cytokines during chronic hepatitis C.
    Scand J Immunol, 63(6): 461-7. [Abstract] [Full-text]
46. Attempted therapeutic immunization in a chimpanzee chronic HBV carrier with a high viral load.
    J Med Primatol, 35(3): 165-71. [Abstract] [Full-text]
47. Mucosal immunization against hepatitis A: antibody responses are enhanced by co-administration of synthetic oligodeoxynucleotides and a novel cationic lipid.
    Vaccine, 24(25): 5300-10. [Abstract] [Full-text]
48. Relationship of smoking and fibrosis in patients with chronic hepatitis C.
    Clin Gastroenterol Hepatol, 4(6): 797-801. [Abstract] [Full-text]
49. Needlestick injuries during medical training.
    J Hosp Infect, 63(3): 263-7. [Abstract] [Full-text]
50. Early impairment of hepatitis C virus specific T cell proliferation during acute infection leads to failure of viral clearance.
    Gut, 55(7): 1012-9. [Abstract] [Full-text]
51. Patients' experiences related to anti-viral treatment for hepatitis C.
    Patient Educ Couns, 62(1): 148-55. [Abstract] [Full-text]
52. Impact of bile duct obstruction on hepatic E. coli infection: role of IL-10.
    Am J Physiol Gastrointest Liver Physiol, 291(1): G91-4. [Abstract] [Full-text]
53. Severe liver injury after initiating therapy with atomoxetine in two children.
    J Pediatr, 148(6): 831-4. [Abstract] [Full-text]
54. Expert Consensus Conference. The screening for hepatitis C virus infection in adults in Italy, May 5-6, 2005.
    Dig Liver Dis, 38(7): 445-51. [Abstract] [Full-text]
55. Punica granatum (pomegranate) flower extract possesses potent antioxidant activity and abrogates Fe-NTA induced hepatotoxicity in mice.
    Food Chem Toxicol, 44(7): 984-93. [Abstract] [Full-text]
56. Coeliac crisis presenting with cytomegalovirus hepatitis.
    Eur J Gastroenterol Hepatol, 18(7): 793-5. [Abstract] [Full-text]
57. Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumour.
    Eur J Gastroenterol Hepatol, 18(7): 785-7. [Abstract] [Full-text]
58. Prognostic value of quantitative liver function tests in viral cirrhosis: a prospective study.
    Eur J Gastroenterol Hepatol, 18(7): 713-20. [Abstract] [Full-text]
59. HCV genotype 4 in Belgium: three distinct patterns among patients from European and African origin.
    Eur J Gastroenterol Hepatol, 18(7): 707-12. [Abstract] [Full-text]
60. Effect of amantadine on depressive symptoms in chronic hepatitis C patients treated with pegylated interferon: a randomized, controlled pilot study.
    Clin Neuropharmacol, 29(3): 138-43. [Abstract] [Full-text]
61. Prolonged lamivudine treatment in patients with chronic active anti-HBe-positive hepatitis.
    Am J Ther, 13(3): 218-22. [Abstract] [Full-text]
62. Prevalence and screening costs of hepatitis C virus among Ugandan blood donors.
    Trop Med Int Health, 11(6): 951-4. [Abstract] [Full-text]
63. Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites.
    Am J Gastroenterol, 101(6): 1390-2. [Abstract] [Full-text]
64. A study of low dose peginterferon alpha-2b with ribavirin for the initial treatment of chronic hepatitis C.
    Am J Gastroenterol, 101(6): 1268-73. [Abstract] [Full-text]
65. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?
    Am J Gastroenterol, 101(6): 1260-7. [Abstract] [Full-text]
66. Sexual dysfunction is highly prevalent among men with chronic hepatitis C virus infection and negatively impacts health-related quality of life.
    Am J Gastroenterol, 101(6): 1235-43. [Abstract] [Full-text]
67. Histamine dihydrochloride: actions and efficacy in the treatment of chronic hepatitis C infection.
    Expert Rev Anti Infect Ther, 4(3): 377-85. [Abstract] [Full-text]
68. Class II cytokine receptor gene cluster is a major locus for hepatitis B persistence.
    Proc Natl Acad Sci U S A, 103(24): 9148-53. [Abstract] [Full-text]
69. Distribution of hepatitis C virus genotypes in the Middle East.
    Int J Infect Dis, 10(4): 272-7. [Abstract] [Full-text]
70. HCV proteins increase expression of heme oxygenase-1 (HO-1) and decrease expression of Bach1 in human hepatoma cells.
    J Hepatol, 45(1): 5-12. [Abstract] [Full-text]
71. Lewis-Sumner syndrome in hepatitis C virus infection: a possible pathogenetic association with therapeutic problems.
    Muscle Nerve, 34(1): 116-21. [Abstract] [Full-text]
72. Genetic changes in hepatitis delta virus from acutely and chronically infected woodchucks.
    J Virol, 80(13): 6469-77. [Abstract] [Full-text]
73. Specific infections, infection-related behavior, and risk of non-Hodgkin lymphoma in adults.
    Cancer Epidemiol Biomarkers Prev, 15(6): 1102-8. [Abstract] [Full-text]
74. Improvement in quality of life measures in patients with refractory hepatitis C, responding to re-treatment with Pegylated interferon alpha -2b and ribavirin.
    Health Qual Life Outcomes, 4: 30. [Abstract] [Full-text]
75. A mathematical model of hepatitis a transmission in the United States indicates value of universal childhood immunization.
    Clin Infect Dis, 43(2): 158-64. [Abstract] [Full-text]
76. Novel mfgl2 antisense plasmid inhibits murine fgl2 expression and ameliorates murine hepatitis virus type 3-induced fulminant hepatitis in BALB/cJ mice.
    Hum Gene Ther, 17(6): 589-600. [Abstract] [Full-text]
77. Current therapy of hepatitis C.
    Scand J Gastroenterol Suppl. [Abstract] [Full-text]
78. Effects on gene expression and viral load of a medicinal extract from Agaricus blazei in patients with chronic hepatitis C infection.
    Int Immunopharmacol, 6(8): 1311-4. [Abstract] [Full-text]
79. Epidemiologic shift in the prevalence of Hepatitis A virus in Saudi Arabia: a case for routine Hepatitis A vaccination.
    Vaccine, 24(27): 5599-603. [Abstract] [Full-text]
80. IGF2 polymorphisms are associated with hepatitis B virus clearance and hepatocellular carcinoma.
    Biochem Biophys Res Commun, 346(1): 38-44. [Abstract] [Full-text]
81. First case of ivermectin-induced severe hepatitis.
    Trans R Soc Trop Med Hyg, 100(8): 795-7. [Abstract] [Full-text]
82. Hepatitis C virus genotypes in southern Taiwan: prevalence and clinical implications.
    Trans R Soc Trop Med Hyg, 100(8): 767-74. [Abstract] [Full-text]
83. Anti-hepatitis B activities of ganoderic acid from Ganoderma lucidum.
    Biotechnol Lett, 28(11): 837-41. [Abstract] [Full-text]
84. Lymphadenopathy resulting from acute hepatitis C infection mimicking metastatic breast carcinoma on FDG PET/CT.
    Clin Nucl Med, 31(7): 379-81. [Abstract] [Full-text]
85. Correlation between genomic DNA copy number alterations and transcriptional expression in hepatitis B virus-associated hepatocellular carcinoma.
    FEBS Lett, 580(15): 3571-81. [Abstract] [Full-text]
86. P2-P4 macrocyclic inhibitors of hepatitis C virus NS3-4A serine protease.
    Bioorg Med Chem Lett, 16(15): 3960-5. [Abstract] [Full-text]
87. Specific gene-expression profiles of noncancerous liver tissue predict the risk for multicentric occurrence of hepatocellular carcinoma in hepatitis C virus-positive patients.
    Ann Surg Oncol, 13(7): 947-54. [Abstract] [Full-text]
88. Adult T-cell leukemia in a liver transplant recipient that did not progress after onset of graft rejection.
    Int J Hematol, 83(5): 429-32. [Abstract] [Full-text]
89. Classic polyarteritis nodosa presenting rare clinical manifestations in a patient with hemophilia A.
    Int J Hematol, 83(5): 420-5. [Abstract] [Full-text]
90. A two-component model for counts of infectious diseases.
    Biostatistics, 7(3): 422-37. [Abstract] [Full-text]
91. Health care access and sociodemographic factors associated with hepatitis B testing in Vietnamese American men.
    J Immigr Minor Health, 8(3): 193-201. [Abstract] [Full-text]
92. GB virus C genotype 1 is rarely transmitted vertically but acquired during infancy in West Africa.
    AIDS, 20(10): 1458-60. [Abstract] [Full-text]
93. Co-infection with HIV and hepatitis C virus in former plasma/blood donors: challenge for patient care in rural China.
    AIDS, 20(10): 1429-35. [Abstract] [Full-text]
94. Host-specific response to HCV infection in the chimeric SCID-beige/Alb-uPA mouse model: role of the innate antiviral immune response.
    PLoS Pathog, 2(6): e59. [Abstract] [Full-text]
95. Impact of double-filtration plasmapheresis in combination with interferon and ribavirin in living donor liver transplant recipients with hepatitis C.
    Transplantation, 81(12): 1747-9. [Abstract] [Full-text]
96. Selection of different 5' untranslated region hepatitis C virus variants during post-transfusion and post-transplantation infection.
    J Viral Hepat, 13(7): 489-98. [Abstract] [Full-text]
97. Lifestyle changes and beliefs regarding disease severity in patients with chronic hepatitis C.
    J Viral Hepat, 13(7): 482-8. [Abstract] [Full-text]
98. Interferon gamma-secreting HCV-specific CD8+ T cells in the liver of patients with chronic C hepatitis: relation to liver fibrosis--ANRS HC EP07 study.
    J Viral Hepat, 13(7): 474-81. [Abstract] [Full-text]
99. Viral kinetics and early prediction of nonresponse to peg-IFN-alpha-2b plus ribavirin in HCV genotypes 1/4 according to HIV serostatus.
    J Viral Hepat, 13(7): 466-73. [Abstract] [Full-text]
100. Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis.
     J Viral Hepat, 13(7): 457-65. [Abstract] [Full-text]
101. Insulin resistance is not associated with liver fibrosis progression in HIV/hepatitis C virus-coinfected patients.
     J Viral Hepat, 13(7): 449-56. [Abstract] [Full-text]
102. Effects of bezafibrate in patients with chronic hepatitis C virus infection: combination with interferon and ribavirin.
     J Viral Hepat, 13(7): 441-8. [Abstract] [Full-text]
103. Re-treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon-alpha-2a (40 kDa) and ribavirin.
     J Viral Hepat, 13(7): 435-40. [Abstract] [Full-text]
104. Hepatic vein transit time of SonoVue: a comparative study with Levovist.
     Radiology, 240(1): 130-5. [Abstract] [Full-text]
105. Possible contribution of serum activin A and IGF-1 in the development of hepatocellular carcinoma in Egyptian patients suffering from combined hepatitis C virus infection and hepatic schistosomiasis.
     Clin Biochem, 39(6): 623-9. [Abstract] [Full-text]
106. Serum laminin assayed by Slot-Blot-ELISA in patients with combined viral hepatitis C and schistosomiasis.
     Clin Biochem, 39(6): 652-7. [Abstract] [Full-text]
107. Efficacy of interferon monotherapy in young adult patients with chronic hepatitis C virus infection.
     J Gastroenterol, 41(5): 470-5. [Abstract] [Full-text]
108. Viral hepatitis and liver cancer: the case of hepatitis C.
     Oncogene, 25(27): 3834-47. [Abstract] [Full-text]
109. Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity.
     Oncogene, 25(27): 3771-7. [Abstract] [Full-text]
110. Southern Europe as an example of interaction between various environmental factors: a systematic review of the epidemiologic evidence.
     Oncogene, 25(27): 3756-70. [Abstract] [Full-text]
111. De novo autoimmune hepatitis following liver transplantation for primary biliary cirrhosis.
     Transplant Proc, 38(5): 1467-70. [Abstract] [Full-text]
112. The impact of nonalcoholic fatty liver disease and the metabolic syndrome on progression of fibrosis in patients with recurrent HCV after liver transplantation.
     Transplant Proc, 38(5): 1440-4. [Abstract] [Full-text]
113. Does cyclosporine have a beneficial effect on the course of chronic hepatitis C infection after renal transplantation?
     Transplant Proc, 38(5): 1329-32. [Abstract] [Full-text]
114. No influence of GB virus C on disease progression in a Danish cohort of HIV-infected men.
     AIDS Res Hum Retroviruses, 22(6): 496-8. [Abstract] [Full-text]
115. Application of functional genomics to the chimeric mouse model of HCV infection: optimization of microarray protocols and genomics analysis.
     Virol J, 3: 37. [Abstract] [Full-text]
116. Application of real-time PCR to quantify hepatitis B virus DNA in chronic carriers in The Gambia.
     Virol J, 3: 23. [Abstract] [Full-text]
117. Synthesis and the biological evaluation of 2-benzenesulfonylalkyl-5-substituted-sulfanyl-[1,3,4]-oxadiazoles as potential anti-hepatitis B virus agents.
     Antiviral Res, 71(1): 7-14. [Abstract] [Full-text]
118. Partner notification for persons with chronic hepatitis B virus infection: use of a syphilis model service.
     Sex Transm Dis, 33(7): 437-40. [Abstract] [Full-text]
119. Rapid improvement of distal vasculitis in PAN related to hepatitis B with alprostadil infusion: a case report.
     Rheumatol Int, 26(10): 928-32. [Abstract] [Full-text]
120. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids.
     Rheumatology (Oxford), 45(7): 842-6. [Abstract] [Full-text]
121. The construction of hepatitis C as a chronic illness.
     Clin Nurs Res, 15(3): 209-24. [Abstract] [Full-text]
122. Immunomodulatory activities of IFN-gamma1b in combination with type I IFN: implications for the use of IFN-gamma1b in the treatment of chronic HCV infections.
     J Interferon Cytokine Res, 26(7): 473-83. [Abstract] [Full-text]
123. Complete genomic sequences for hepatitis C virus subtypes 6e and 6g isolated from Chinese patients with injection drug use and HIV-1 co-infection.
     J Med Virol, 78(8): 1061-9. [Abstract] [Full-text]
124. Case report: Hepatitis A preceding Guillain-Barré syndrome.
     J Med Virol, 78(8): 1011-4. [Abstract] [Full-text]
125. Validation of single real-time TaqMan PCR assay for the detection and quantitation of four major genotypes of hepatitis E virus in clinical specimens.
     J Med Virol, 78(8): 1076-82. [Abstract] [Full-text]
126. Early decrease in circulating dendritic cells number after liver transplantation could favor hepatitis C virus recurrence.
     J Med Virol, 78(8): 1070-5. [Abstract] [Full-text]
127. Detection of a hepatitis B surface antigen variant emerging in a patient with chronic lymphocytic leukaemia treated with fludarabine.
     J Med Virol, 78(8): 1043-6. [Abstract] [Full-text]
128. Molecular epidemiology of hepatitis B virus in the United Republic of Tanzania.
     J Med Virol, 78(8): 1035-42. [Abstract] [Full-text]
129. Basal core promoter, precore region mutations of HBV and their association with e antigen, genotype, and severity of liver disease in patients with chronic hepatitis B in India.
     J Med Virol, 78(8): 1047-54. [Abstract] [Full-text]
130. Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy.
     J Med Virol, 78(8): 1025-34. [Abstract] [Full-text]
131. Studies on TAQ1 polymorphism in the 3'untranslated region of IL-12P40 gene in HCV patients infected predominantly with genotype 3.
     J Med Virol, 78(8): 1055-60. [Abstract] [Full-text]
132. Distinct changing profiles of hepatitis A and E virus infection among patients with acute hepatitis, patients on maintenance hemodialysis and healthy individuals in Japan.
     J Med Virol, 78(8): 1015-24. [Abstract] [Full-text]
133. Persistent infection of hepatitis B virus is involved in high rate of p16 methylation in hepatocellular carcinoma.
     Mol Carcinog, 45(7): 530-6. [Abstract] [Full-text]
134. Seroepidemiology of hepatitis A and hepatitis B virus in Luxembourg.
     Epidemiol Infect, 134(4): 808-13. [Abstract] [Full-text]
135. A syringe exchange programme in prison as prevention strategy against HIV infection and hepatitis B and C in Berlin, Germany.
     Epidemiol Infect, 134(4): 814-9. [Abstract] [Full-text]
136. An evaluation and comparison of three commonly used statistical models for automatic detection of outbreaks in epidemiological data of communicable diseases.
     Epidemiol Infect, 134(4): 863-71. [Abstract] [Full-text]
137. An outbreak of hepatitis A in Southern Italy: the case for vaccinating food handlers.
     Epidemiol Infect, 134(4): 799-802. [Abstract] [Full-text]
138. Exposure to school children as a risk factor in a community outbreak of hepatitis A in young adults: a case control study.
     Epidemiol Infect, 134(4): 803-7. [Abstract] [Full-text]
139. Autochthonous hepatitis E virus infection in Germany with sequence similarities to other European isolates.
     Infection, 34(3): 173-5. [Abstract] [Full-text]
140. Screening for viral hepatitis among male non-drug-abuse prisoners.
     Scand J Gastroenterol, 41(8): 969-73. [Abstract] [Full-text]
141. A statistical model predicting high hepatocyte proliferation index and the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis.
     Aliment Pharmacol Ther, 24(1): 129-36. [Abstract] [Full-text]
142. Sustained virological response to peginterferon plus ribavirin in chronic hepatitis C genotype 1 patients is associated with a persistent Th1 immune response.
     Aliment Pharmacol Ther, 24(1): 117-28. [Abstract] [Full-text]
143. Thalidomide-induced severe hepatotoxicity.
     Pharmacotherapy, 26(7): 1018-22. [Abstract] [Full-text]
144. Patterns in the offering of hepatitis B prophylaxis by US emergency department physicians.
     Infect Control Hosp Epidemiol, 27(7): 764-6. [Abstract] [Full-text]
145. Hepatitis C virus triggers mitochondrial permeability transition with production of reactive oxygen species, leading to DNA damage and STAT3 activation.
     J Virol, 80(14): 7199-207. [Abstract] [Full-text]
146. Evaluating replication-defective vesicular stomatitis virus as a vaccine vehicle.
     J Virol, 80(14): 6993-7008. [Abstract] [Full-text]
147. Hepatitis C virus entry depends on clathrin-mediated endocytosis.
     J Virol, 80(14): 6964-72. [Abstract] [Full-text]
148. Neonatal hepatitis in 2 siblings with Seckel syndrome.
     Pediatr Dev Pathol, 9(1): 81-5. [Abstract] [Full-text]
149. Changes in hepatitis C virus (HCV) viral load and interferon-alpha levels in HIV/HCV-coinfected patients treated with highly active antiretroviral therapy.
     J Acquir Immune Defic Syndr, 42(3): 293-7. [Abstract] [Full-text]
150. Immunosuppression, hepatitis C infection, and acute renal failure in HIV-infected patients.
     J Acquir Immune Defic Syndr, 42(3): 368-72. [Abstract] [Full-text]

© 2006-2008 Hepatitis Research Today. All Rights Reserved.